Status | Study |
RECRUITING |
Study Name: Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities Condition: Malaria Date: 2023-11-10 Interventions: Mesh is one of the first spatial repellent tools to provide long-lasting protection to users, with predicted efficacy of 6-months.The active |
RECRUITING |
Study Name: A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria Condition: Malaria Date: 2023-09-29 Interventions: Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection |
COMPLETED |
Study Name: Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers. Condition: Malaria Date: 2023-06-26 Interventions: PQP hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water |
RECRUITING |
Study Name: Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults Condition: Malaria Date: 2023-06-19 Interventions: Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pasto |
NOT_YET_RECRUITING |
Study Name: Pan-Malaria Transmission-Blocking Vaccine AnAPN1 Condition: Date: 2023-06-07 Interventions: AnAPN1 is a recombinant protein expressed in Escherichia coli.It consists of the UF6b construct, derived from the sequence of the Anopheles gamb |
RECRUITING |
Study Name: Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults Condition: Malaria Date: 2023-05-26 Interventions: MAM01 will be administered via IV or SC route |
COMPLETED |
Study Name: Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country Condition: Malaria Date: 2022-10-27 Interventions: One immunization every 4 weeks for 3 months (total 3 immunizations) |
Recruiting |
Study Name: Rosiglitazone Adjunctive Therapy for Severe Malaria in Children Condition: Malaria Date: 2015-12-09 Interventions: Drug: Rosiglitazone This is th |
Recruiting |
Study Name: Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland Condition: Malaria Date: 2014-12-08 Interventions: Drug: dihydroartemisinin-piperaquine (DHAp) |
Active, not recruiting |
Study Name: Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults Condition: Malaria Date: 2014-06-11 Interventions: Biological: FMP012 with AS01B adjuvant system |